. Validation of hits from epigenetic drug screen.
(A) Tenovin-1 (p53 activator), one of the top three positive compounds from the cell-based screen ( Figure 1A) , was subjected to cell viability assay using MTS. Treatments with tenovin-1 did not significantly increase the viability of mutant Htt-expressing neurons (ANOVA, *P < 0.0001 compared to Htt-25Q (0 µM); P = 0.591, Htt-72Q (0.02 µM) vs Htt-72Q (0 µM); P = 0.355, Htt-72Q (0.2 µM) vs Htt-72Q (0 µM); P = 0.168, Htt-72Q (2 µM) vs Htt-72Q (0 µM); n = 6-12 wells per group).
(B) AG-014699 (PARP1 inhibitor), another screen hit, was subjected to cell viability assay as in (A).
There is no significant difference in survival between the AG-014699-and vehicle-treated Htt-72Q neurons (ANOVA, *P < 0.0001 compared to Htt-25Q (0 µM); P = 0.142, Htt-72Q (0.02 µM) vs Htt-72Q (0 µM); P = 0.254, Htt-72Q (0.2 µM) vs Htt-72Q (0 µM); P = 0.781, Htt-72Q (2 µM) vs Htt-72Q (0 µM); n = 12 wells per groups).
Data are presented as mean + SEM.
Figure S2. Inhibition of DNMTs attenuates mutant Htt aggregates in primary cortical neurons
(A) DIV 5 mouse primary cortical neurons were infected with Htt-72Q lentivirus and treated with decitabine or vehicle (DMSO). RNA was prepared at DIV 10 and subjected to qRT-PCR analysis for Htt-72Q (human). β-actin and Hprt were used as reference genes. Decitabine did not decrease the levels of Htt-72Q mRNA compared to vehicle (ANOVA, n = 6 independent experiments).
(B) DIV 5 cortical neurons were infected with Htt lentivirus and treated with decitabine (0.2 µM) or DMSO. Neurons were fixed at DIV 11-12 and subjected to indirect immunofluorescence with a specific mouse monoclonal Htt antibody EM48, which preferentially detects aggregated mutant protein. Nuclei were labeled with Hoechst 33342. Images were captured using an Operetta high-content imaging system (PerkinElmer) with a 20× objective lens. Bar, 100 µm.
(C) EM48 immunofluorescence intensity in (B) was quantified using an ImageJ-based macro. Decitabine significantly decreased the levels of mutant Htt aggregates in Htt-72Q-expressing primary cortical neurons (ANOVA, *P < 0.0001 vs. Htt-72Q-DMSO, n = 18 wells from 6 independent experiments).
(D) Cortical neurons transduced and processed as in (A) were directly harvested in SDS sample buffer at DIV 10 and subjected to immunoblotting with anti-Htt EM48 monoclonal antibody. Blot was reprobed with anti-β-actin antibody. Representative immunoblot from 3 independent experiments is shown. Decitabine could decrease the levels of aggregated high molecular weight mutant Htt in a stacking gel (*).
Data in (A) and (C) are presented as mean + SEM. (A) DIV 5 cortical neurons transduced with lentivirus expressing Htt-72Q or Htt-25Q fragment were treated with the indicated drugs or DMSO (= 0 µM) and subjected to MTS assay at DIV 14. Decitabine, but not zebularine, increased the viability of mutant Htt-expressing neurons (ANOVA, *P < 0.0001 compared to Htt-72Q (0 µM); no significant difference in survival between zebularine and vehicle-treated Htt-72Q neurons; n = 8-18 wells per group, 3 independent experiments).
(B) Primary cortical neurons transduced and treated with 5-azacytidine were subjected to MTS assay as in (A). There was no significant difference in survival between 5-azacytidine-and vehicle-treated Htt-72Q neurons (ANOVA, n = 6-15 wells per group, 3 independent experiments).
(C) Primary cortical neurons were transduced and treated as in (A) and subjected to neurofilament (NF) immunofluorescence. There was no significant difference in NF immunofluorescence intensity between 5-azacytidine-and vehicle-treated Htt-72Q cortical neurons (ANOVA, n = 6-15 wells per group, 3 independent experiments) (D) Primary striatal neurons transduced with Htt-25Q or Htt-72Q lentivirus at DIV 4 were treated with 5-azacytidine or DMSO. Seven days later, neurons were subjected to NF immunofluorescence. There was no significant difference in NF immunofluorescence intensity between 5-azacytidine-and vehicle-treated Htt-72Q striatal neurons (ANOVA, n = 9-17 wells, 3 independent experiments).
Data are presented as mean + SEM. (A) Decitabine (0.2 mM in saline) was first incubated at 37°C for indicated number of days in vitro and then added to the culture media at a final concentration 0.2 µM of DIV 5 primary cortical neurons transduced with Htt-25Q or Htt-72Q lentivirus. The neuroprotective activity of decitabine was tested using MTS assay at DIV 14. Decitabine lost its activity when tested after 11 days of incubation (ANOVA, *P < 0.0001 compared to Htt-72Q plus vehicle, no difference between Htt-72Q plus vehicle vs Htt-72Q plus decitabine preincubated for 11 days, n = 9 wells, 3 independent experiments).
(B) Similar experiments were performed with FdCyd as in (A). In contrast to decitabine, FdCyd preincubated for 11 or 45 days showed neuroprotective effects comparable to FdCyd with no preincubation (ANOVA, *P < 0.0001 compared to Htt-72Q plus vehicle, n = 9 wells, 3 independent experiments).
Data are presented as mean + SEM. Table S1 . List of compounds used in the epigenetic drug screen
